The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

The preservative is in a small share of flu shots and has been studied for decades. Experts say it’s safe — despite Kennedy’s long opposition.

"This is a very clear effort to shine a light on this anti-vaccine trope: that thimerosal is somehow dangerous.” ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

New data hint at a role for the AS01 adjuvant in vaccines for herpes zoster and respiratory syncytial virus in protecting ...